

High patient burden with moderate-to-severe atopic dermatitis

July 5 2018



(HealthDay)—Patients with moderate/severe atopic dermatitis (AD)



have higher patient-reported burden than those with mild AD, regardless of disease control, according to a study published online July 3 in *JAMA Dermatology*.

Eric L. Simpson, M.D., from the Oregon Health & Science University in Portland, and colleagues characterized the patient-reported burden of AD in a cross-sectional study using data from six academic medical centers. Using the Patient-Oriented Scoring Atopic Dermatitis, they stratified 1,519 adults with AD by AD severity as mild or moderate/severe. Those with moderate/severe disease using systemic immunomodulators/phototherapy were further stratified according to disease control.

The researchers found that the 830 patients with moderate/severe AD reported more severe itching and pain, greater adverse effects on sleep, higher prevalence of anxiety and depression (50.2 versus 27.3 percent), and greater health-related quality-of-life impairment compared to mild AD (689 patients). For patients with moderate/severe AD, higher burdens of itch and sleeping symptoms were reported for those with inadequate disease control despite treatment with systemic immunomodulators or phototherapy versus those with controlled disease; this included more days per week with itchy skin (5.7 versus 2.7) and higher proportions with itch duration greater than half a day (22.8 versus 2.9 percent).

"Regardless of <u>disease control</u>, the burden of moderate/severe AD was higher than mild AD, suggesting a need for more effective therapies for moderate/severe disease," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Regeneron Pharmaceuticals and Sanofi, which funded the study.



More information: Abstract/Full Text

Copyright © 2018 HealthDay. All rights reserved.

Citation: High patient burden with moderate-to-severe atopic dermatitis (2018, July 5) retrieved 4 May 2024 from

https://medicalxpress.com/news/2018-07-high-patient-burden-moderate-to-severe-atopic.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.